Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer
The average exposure of edoxaban was not affected by enzalutamide. However, bioequivalence could not be established due to the broader than anticipated CI. Despite this, the larger variability in edoxaban exposure is not expected to be clinically relevant, supporting the safe co-administration of both drugs.
Authors
- Alex L.T. Imholz
- Niven Mehra (ORCID: https://orcid.org/0000-0002-4794-1831)
- Diederik M. Somford (ORCID: https://orcid.org/0000-0002-5277-6586)
- Nielka P. van Erp (ORCID: https://orcid.org/0000-0003-1553-178X)
- Paul Hamberg (ORCID: https://orcid.org/0000-0002-8223-0250)
- Emmy Boerrigter (ORCID: https://orcid.org/0000-0002-3041-6774)
- Inge M. van Oort (ORCID: https://orcid.org/0000-0002-8002-1869)
- Catharina J. P. Op ’t Hoog (ORCID: https://orcid.org/0009-0003-4204-5346)
- Anouk van Kleef
Institutions
- Radboud University Nijmegen (NL)
- Radboud University Medical Center (NL)
- Sint Franciscus Gasthuis (NL)
- Canisius-Wilhelmina Ziekenhuis (NL)
- Deventer Ziekenhuis (NL)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-11-23
- DOI
- https://doi.org/10.1002/bcp.70369
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Astellas Pharma